Rilzabrutinib demonstrates rapid and durable clinical activity for immune thrombocytopenia
1. Rilzabrutinib was active and 400mg twice daily was identified as the dose for further testing with low-level toxic effects. ...
Tag: Bruton’s tyrosine kinase (BTK) inhibitor
#VisualAbstract: Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
1. The Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib when compared to placebo treatment in multiple sclerosis patients showed the ability ...
Evobrutinib reduces imaging findings of multiple sclerosis but not clinical progression
1. The Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib when compared to placebo treatment in multiple sclerosis patients showed the ability ...